Drilldown: Medicines
Appearance
Use the filters below to narrow your results.
generic:
mechanism:
Monoamine releasing agent (8) ·
Dopamine/norepinephrine reuptake inhibitor (5) ·
Mu-opioid receptor agonist (4) ·
Potent mu-opioid receptor agonist (3) ·
Cathinone analogue; monoamine reuptake inhibitor (2) ·
Dopamine and norepinephrine reuptake inhibitor (2) ·
Norepinephrine–dopamine reuptake inhibitor (2)
None (58) ·
Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) ·
Limited data; fluoxetine has reassuring data but olanzapine carries metabolic-syndrome and gestational diabetes signals.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
None (58) ·
US Schedule II (single-entity); Schedule III–V (combination products by content). (1) ·
[[USLegal:Prescription only|Rx-only]] in US. Carries the '''antidepressant Boxed Warning''' for suicidality in children/adolescents/young adults and the atypical-neuroleptic '''Boxed Warning''' for increased mortality in elderly dementia patients'"`UNIQ--ref-0000154F-QINU`"' (1)
Showing below up to 60 results in range #1 to #60.
2
3
4
A
B
C
D
E
F
H
I
L
M
N
O
P
- Papaverine
- Pentazocine
- Pentedrone
- Pharmacopedia:Pharmacogenomics sandbox/Codeine
- Phenethylamine
- Phenylpiracetam
- Prolintane
- Propylhexedrine


